AFCAPS/TexCAPS Trial

< AFCAPS(Redirected from AFCAPS)
Jump to: navigation, search

Low Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low LDL
High LDL

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Prognosis and Complications

Diagnosis

Laboratory Findings

Treatment

Medical Therapy

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

AFCAPS/TexCAPS Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of AFCAPS/TexCAPS Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on AFCAPS/TexCAPS Trial

CDC on AFCAPS/TexCAPS Trial

AFCAPS/TexCAPS Trial in the news

Blogs on AFCAPS/TexCAPS Trial

Directions to Hospitals Treating Low density lipoprotein

Risk calculators and risk factors for AFCAPS/TexCAPS Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for AFCAPS/TexCAPS.

Overview

Lovastatin 20-40 mg daily (in addition to low-saturated ad low-colesterol diet) reduced the incidence of first major acute cardiovascular event (MACE) during a follow-up of 5.2 years, in this study involving 5608 men and 997 women with average total cholesterol and LDL levels and low HDL levels[1].

References

  1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA; et al. (1998). "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.". JAMA. 279 (20): 1615–22. PMID 9613910. 

Linked-in.jpg